Don't Rush to Crush 4th Edition Updates
March 2024: one new monograph – trientine, plus updated information for decitabine and cedazuridine (Inqovi).
December 2023: four new monographs – azacitadine, lenacapavir, mobocertinib, sotorasib. There is updated advice for the administration of colestyramine, and venetoclax by enteral feeding tube. The vandetanib monograph has been updated to reflect changes in product availability.
September 2023: six new monographs – asciminib, avatrombopag, belzutifan, finerenone, ivosidenib, zanbrutinib. New information is available for acalabrutinib, and updated advice for venlafaxine in response to user feedback. Instructions for part-dosing have been included for lisdexamphetamine in response to the shortage of 20mg and 30 mg capsules. The monographs for cefuroxime, ivacaftor & lumacaftor (Orkambi), misoprostol, and prucalopride have been updated to reflect changes in product availability.
June 2023: hydromorphone monograph updated to reflect changes in product availability.
March 2023: three new monographs – maribavir, pemigatenib, vericiguat. There is new information for binimetinib and encorafenib for people with swallowing difficulties.
December 2022: five new monographs – decitabine/cedazuridine, diroximel fumurate, gilteritinib, ripretinib, selinexor. There is new information for nirmatrelvir/ritonavir (Paxlovid) for people with enteral feeding tubes or swallowing difficulties and new information for posaconazole for people with enteral feeding tubes. There is updated advice for ibuprofen, irbesartan and lansoprazole in response to user feedback. The monographs for ertugliflozin, leflunomide, olaparib, and roxithromycin have been updated to reflect changes in product availability.
June 2022: four new monographs – alpelisib, amifampridine, larotrectrenib, pentosan polysulfate. There is new information for molnupiravir (Lagevrio) for people with swallowing difficulties and updated advice for rifampicin in response to user feedback. The monographs for clozapine, dasatinib, dipyridamole and aspirin, efavirenz, maviret, phentermine, and ribavirin have been updated to reflect changes in product availability.
May 2022: the Bosentan monograph has been updated to correct an error in the What to do for doses less than a whole tablet section.
March 2022: five new medicines including two new COVID-19 treatments – molnupiravir (Lagevrio) and nirmatrelvir plus ritonavir (Paxlovid).